Mycamine is a brand name of micafungin, approved by the FDA in the following formulation(s):
MYCAMINE (micafungin sodium - injectable; iv (infusion))
Manufacturer: ASTELLAS
Approval date: March 16, 2005
Strength(s): 50MG/VIAL [RLD]
Manufacturer: ASTELLAS
Approval date: June 27, 2006
Strength(s): 100MG/VIAL [RLD]
Has a generic version of Mycamine been approved?
No. There is currently no therapeutically equivalent version of Mycamine available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Mycamine. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Polypeptide compound and a process for preparation thereof
Patent 5,376,634
Issued: December 27, 1994
Inventor(s): Iwamoto; Toshiro & Fujie; Akihiko & Nitta; Kumiko & Tsurumi; Yasuhisa & Shigematsu; Nobuharu & Kasahara; Chiyoshi & Hino; Motohiro & Okuhara; Masakuni & Sakane; Kazuo & Kawabata; Kohji & Ohki; Hidenori
Assignee(s): Fujisawa Pharmaceutical Co., Ltd.
A polypeptide compound having antimicrobial activity of the following general formula: ##STR1## wherein R.sup.1 is hydrogen or acyl group, R.sup.2 is hydroxy or acyloxy, R.sup.3 is hydroxysulfonyloxy, and R.sup.4 is hydrogen or carbamoyl, with proviso that R.sup.1 is not palmitoyl, when R.sup.2 is hydroxy, R.sup.3 is hydroxysulfonyloxy and R.sup.4 is carbamoyl, and a pharmaceutically acceptable salt thereof.Patent expiration dates:
- December 27, 2011✓✓
- December 27, 2011
Cyclic hexapeptides having antibiotic activity
Patent 6,107,458
Issued: August 22, 2000
Inventor(s): Ohki; Hidenori & Tomishima; Masaki & Yamada; Akira & Takasugi; Hisashi
Assignee(s): Fujisawa Pharmaceutical Co., Ltd.
This invention relates to new polypeptide compounds represented by the following formula (I): ##STR1## wherein R.sup.1 is as defined in the description and pharmaceutically acceptable salt thereof which have antimicrobial activities (especially, antifungal activities), inhibitory activity on .beta.-1,3-glucan synthase, to process for preparation thereof, to a pharmaceutical composition comprising the same, and to a method for the prophylactic and/or therapeutic treatment of infectious diseases including Pneumocystis carinii infection (e.g. Pneumocystis carinii pneumonia) in a human being or an animal.Patent expiration dates:
- March 16, 2019✓✓✓
- March 16, 2019✓✓✓
- March 16, 2019
Cyclic hexapeptides having antibiotic activity
Patent 6,265,536
Issued: July 24, 2001
Inventor(s): Ohki; Hidenori & Tomishima; Masaki & Yamada; Akira & Takasugi; Hisashi
Assignee(s): Fujisawa Pharmaceutical Co., Ltd.
This invention relates to new polypeptide compounds represented by the following formula (I): ##STR1## wherein R.sup.1 is as defined in the description and pharmaceutically acceptable salt thereof which have antimicrobial activities (especially, antifungal activities), inhibitory activity on .beta.-1,3-glucan synthase, to process for preparation thereof, to a pharmaceutical composition comprising the same, and to a method for the prophylactic and/or therapeutic treatment of infectious diseases including Pneumocystis carinii infection (e.g. Pneumocystis carinii pneumonia) in a human being or an animal.Patent expiration dates:
- September 29, 2015✓✓✓
- September 29, 2015✓✓✓
- September 29, 2015
Stabilized pharmaceutical composition in lyophilized form
Patent 6,774,104
Issued: August 10, 2004
Inventor(s): Seiji; Sawai & Akihiro; Kasai & Kazumi; Otomo
Assignee(s): Fujisawa Pharmaceutical Co., Ltd.
A stabilized pharmaceutical composition in lyophilized form comprising: a cyclic polypeptide compound represented by the general formula (I): wherein R1 is a hydrogen atom or an acyl group and R2 and R3 are, the same or different, a hydrogen atom or a hydroxyl group, or a salt thereof and the stabilizer.Patent expiration dates:
- January 8, 2021✓✓
- January 8, 2021✓✓
- January 8, 2021
Related Exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- January 22, 2011 - TREATMENT OF PATIENTS WITH CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONIS AND ABSCESSES
See also...
- Mycamine Consumer Information (Drugs.com)
- Mycamine Consumer Information (Wolters Kluwer)
- Mycamine Consumer Information (Cerner Multum)
- Mycamine Advanced Consumer Information (Micromedex)
- Mycamine AHFS DI Monographs (ASHP)
- Micafungin Consumer Information (Wolters Kluwer)
- Micafungin Consumer Information (Cerner Multum)
- Micafungin Intravenous Advanced Consumer Information (Micromedex)
- Micafungin Sodium AHFS DI Monographs (ASHP)
No comments:
Post a Comment